EUVIMEDEUVIMED entdecken
CrossrefInfokarte

Sex differences in chemotherapy-induced neuropathic pain: mechanisms and pharmacotherapy

Xuewei Wu, Litao Chen, Yushan Chen, Yixin Liu, Xiaowei Chen

Journal of Pharmacy and Pharmacology · 2026-03-05 · 78 (3)

DOI: 10.1093/jpp/rgag025 ↗
AbstractBibliografische Angaben

Abstract

Abstract Objectives Chemotherapy-induced peripheral neuropathy (CIPN) is a common and serious side effect of cancer treatment. Studies have shown that there is significant sexual dimorphism in animal models, molecular mechanisms and drug treatment responses of CIPN-related pain. This review systematically explores these sex differences in CIPN. Key findings Mechanistically, the pain sensitivity of female mice is mainly dependent on the IL-23/IL-17A/TRPV1 signaling axis, bidirectionally regulated by estrogen and its receptor α (ER-α). In contrast, male mice are more driven by TLR9-mediated macrophage activation and subsequent TNF/CXCL1 release. Pharmaco-therapeutically, both pre-clinical and clinical studies of duloxetine have shown that females may have better efficacy. The efficacy of κ-opioid receptor (KOR) agonist, resolvin D5 (RvD5), Mitragynine, sphingosine-1-phosphate receptor 1 (S1PR1) antagonist and adenosine A3 receptor (A3AR) agonist also varies by sex and type of chemotherapy drugs. Conclusions Sex is a crucial biological variable in CIPN, influencing drug efficacy through sex-specific neuroimmune mechanisms and hormonal regulation. These findings underscore the necessity of incorporating sex as a key variable in analgesic development and clinical practice to achieve personalized pain management in CIPN patients.

Wissen, das zu Ihrer Arbeit passt.

Vom kostenlosen Einstieg über die persönliche Recherche bis zur vollständigen Research Suite.

Tarife ansehen →

Sind alle Verlagsvolltexte enthalten?

Nein. Bibliografische Nachweise, Abstracts und Volltexte sind unterschiedliche Inhalte. Ob ein Volltext verfügbar ist, hängt von der Quelle, Open Access und Ihren vorhandenen Lizenzen ab. Ein EUVIMED-Tarif ersetzt keine zusätzlichen Verlagsrechte.

Tarife ansehen →